<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medgen</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская генетика</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Genetics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-7998</issn><publisher><publisher-name>Publishing House «Genius Media» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1234/XXXX-XXXX-2016-6-19-24</article-id><article-id custom-type="elpub" pub-id-type="custom">medgen-138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Связь клинико-морфологических особенностей и мутационного статуса гена BRAF в качестве прогностического фактора у больных меланомой кожи</article-title><trans-title-group xml:lang="en"><trans-title>Association between BRAF gene mutation status and clinical-morphological features of cutaneous melanoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кит</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kit</surname><given-names>O. I.</given-names></name></name-alternatives><email xlink:type="simple">rnioi@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Водолажский</surname><given-names>Д. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vodolazhsky</surname><given-names>D. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ефимова</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Efimova</surname><given-names>I. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Златник</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Zlatnik</surname><given-names>E. Yu.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочуев</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochuev</surname><given-names>S. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский научно-исследовательский онкологический институт</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov Research Institute of Oncology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>07</day><month>10</month><year>2016</year></pub-date><volume>15</volume><issue>6</issue><fpage>19</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кит О.И., Водолажский Д.И., Ефимова И.Ю., Златник Е.Ю., Кочуев С.С., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Кит О.И., Водолажский Д.И., Ефимова И.Ю., Златник Е.Ю., Кочуев С.С.</copyright-holder><copyright-holder xml:lang="en">Kit O.I., Vodolazhsky D.I., Efimova I.Y., Zlatnik E.Y., Kochuev S.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medgen-journal.ru/jour/article/view/138">https://www.medgen-journal.ru/jour/article/view/138</self-uri><abstract><p>Меланома кожи - злокачественное заболевание человека с высоким риском метастазирования. В странах с преимущественно белым населением меланома входит в первую десятку наиболее социально значимых категорий опухолей, как в отношении заболеваемости, так и смертности. Оценка ряда морфологических характеристик новообразования имеет существенное значение при определении прогноза течения заболевания и формирования групп риска у больных меланомой кожи. Целью настоящего исследования стало определение ассоциаций между мутационным статусом гена BRAF и клинико-морфологическими особенностями меланомы кожи у пациентов Юга России, проходившими плановое лечение в ФГБУ РНИОИ МЗ РФ в 2013-2015 гг. Молекулярно-генетическое исследование экзона 15 гена BRAF проведено методами прямого секвенирования по Сэнгеру и RT-PCR у 100 пациентов Юга России с морфологически подтвержденным диагнозом меланома кожи. Установлено, что присутствие мутаций в гене BRAF было достоверно связано с увеличением уровня инвазии по Кларку. Также наблюдалось статистически достоверное повышение частоты изъязвления опухоли на 54% у пациентов с наличием активирующих мутаций V600. Обнаружено, что опухоли с активирующими мутациями в гене BRAF чаще возникали на участках кожи, подверженных периодической солнечной инсоляции (туловище). Опухоли без мутаций в гене BRAF преобладали на участках кожи с хроническим солнечным облучением (голова и шея). Частота соматических мутаций V600 в гене BRAF составила 57% (57 из 100 пациентов). В рамках настоящего исследования в гене BRAF были выявлены три варианта мутаций с различными частотами встречаемости: p.V600E (88%), p.V600K (10%) и V600K601&gt;E (2%). У пациентов моложе 50 лет частота встречаемости мутаций V600 была достоверно больше, чем в группе пациентов старше 50 лет. Также для пациентов моложе 50 лет было характерно отсутствие мутаций V600K и более высокая частота встречаемости мутаций V600E (в 1,7 раза).</p></abstract><trans-abstract xml:lang="en"><p>Skin melanoma - a malignant disease of the person with a high risk of metastasis. In countries with a predominantly white population of melanoma among the top ten most socially important categories of tumors, both in terms of morbidity and mortality. Estimation of some morphological characteristics of tumors is essential in determining the prognosis of the disease and the formation of high-risk groups in patients with melanoma. The aim of this study was to determine the association between the mutational status of BRAF gene, and clinical and morphological features of the skin melanoma patients of the South of Russia. Molecular genetic study of exon 15 of BRAF performed direct sequencing method of Sanger and by RT-PCR in 100 patients with a Russian South morphologically confirmed diagnosis of skin melanoma. It is found that the presence of mutations in the BRAF gene was significantly associated with an increased level of infestation by Clark. Also, there was a statistically significant increase in the frequency of tumor ulceration by 54% in patients with the presence of activating mutations V600. It has been found that tumors with activating mutations in the BRAF gene were more frequent in areas of skin exposed to periodic solar insolation (trunk). Tumors without mutations in the BRAF gene prevailed on the areas of skin with chronic sun exposure (head and neck). The overall frequency of somatic symptoms V600 mutations in the BRAF gene was 57% (57 of 100 patients). In this study the gene in BRAF have been identified mutations three options with different frequencies of occurrence: p.V600E (88%), p.V600K (10%) and K601&gt; E (2%). In patients younger than 50 years, the frequency of occurrence V600 mutations was significantly higher than in the group of patients older than 50. Also, for patients younger than 50 years has been characterized by the absence of mutations V600K and a higher incidence of V600E mutation (1.7 times).</p></trans-abstract><kwd-group xml:lang="ru"><kwd>меланома кожи</kwd><kwd>мутации</kwd><kwd>BRAF</kwd><kwd>melanoma</kwd><kwd>mutations</kwd><kwd>BRAF</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bertolotto C. Melanoma: from melanocyte to genetical Alterations and clinicaloptions // Scientifica. - 2013. 2013:635203.</mixed-citation><mixed-citation xml:lang="en">Bertolotto C. Melanoma: from melanocyte to genetical Alterations and clinicaloptions // Scientifica. - 2013. 2013:635203.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) / Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. - М., 2016. - 250 с.</mixed-citation><mixed-citation xml:lang="en">Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) / Под ред. Каприна А.Д., Старинского В.В., Петровой Г.В. - М., 2016. - 250 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Davies M.A., Samuels Y. Analysis of the genome to personalize therapy for melanoma // Oncogene. - 2010. - № 29(41). - Р. 5545-5555.</mixed-citation><mixed-citation xml:lang="en">Davies M.A., Samuels Y. Analysis of the genome to personalize therapy for melanoma // Oncogene. - 2010. - № 29(41). - Р. 5545-5555.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Davies H., Bignell G.R., Cox C. et al. Mutations of the BRAF gene in human cancer // Nature. - 2002. - № 417 (6892). - P. 949-954.</mixed-citation><mixed-citation xml:lang="en">Davies H., Bignell G.R., Cox C. et al. Mutations of the BRAF gene in human cancer // Nature. - 2002. - № 417 (6892). - P. 949-954.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Long G.V., Menzies A.M., Nargial A.M. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma // J. Clin. Oncol. - 2011. - № 29. - Р. 1239-1246.</mixed-citation><mixed-citation xml:lang="en">Long G.V., Menzies A.M., Nargial A.M. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma // J. Clin. Oncol. - 2011. - № 29. - Р. 1239-1246.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Balch C.M., Soong S.-J., Gershenwald J.E. et al. Prognostic factors analysis of 17600 melanoma patient: validation of the American Joint Committee on cancer melanoma staging system // J. Clin. Oncol. - 2001. - Vol. 19. - P. 3622-3634.</mixed-citation><mixed-citation xml:lang="en">Balch C.M., Soong S.-J., Gershenwald J.E. et al. Prognostic factors analysis of 17600 melanoma patient: validation of the American Joint Committee on cancer melanoma staging system // J. Clin. Oncol. - 2001. - Vol. 19. - P. 3622-3634.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hmonen S. Prognosis of primary melanoma // Scand. J. Surg. - 2002. - Vol. 91. - P. 166-171.</mixed-citation><mixed-citation xml:lang="en">Hmonen S. Prognosis of primary melanoma // Scand. J. Surg. - 2002. - Vol. 91. - P. 166-171.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Grande Sarpa H., Reinke K., Shaikh L. et al. Prognostic significance of extent of ulceration in primary cutaneus melanoma // Am. J. Surg. Pathol. - 2006. - Vol. 30. - P. 1396-1400.</mixed-citation><mixed-citation xml:lang="en">Grande Sarpa H., Reinke K., Shaikh L. et al. Prognostic significance of extent of ulceration in primary cutaneus melanoma // Am. J. Surg. Pathol. - 2006. - Vol. 30. - P. 1396-1400.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Maddoni N., Setaluri V. Prognostic significance of melanoma differentiation and trans-differentiation // Cancers (Basel). - 2010. - Jun. - 2(2). - Р. 989-999.</mixed-citation><mixed-citation xml:lang="en">Maddoni N., Setaluri V. Prognostic significance of melanoma differentiation and trans-differentiation // Cancers (Basel). - 2010. - Jun. - 2(2). - Р. 989-999.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Кит О.И., Водолажский Д.И., Златник Е.Ю. и др. Сравнительная характеристика мутационного статуса гена BRAF в зависимости от клинико-морфологических особенностей меланомы кожи // Современные проблемы науки и образования. - 2015. - № 5.; URL: http://www.science-education.ru/ru/article/view?id = 22900 (дата обращения: 20.02.2016).</mixed-citation><mixed-citation xml:lang="en">Кит О.И., Водолажский Д.И., Златник Е.Ю. и др. Сравнительная характеристика мутационного статуса гена BRAF в зависимости от клинико-морфологических особенностей меланомы кожи // Современные проблемы науки и образования. - 2015. - № 5.; URL: http://www.science-education.ru/ru/article/view?id = 22900 (дата обращения: 20.02.2016).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Elder D.E., Van Belle P., Elenitsas R. et al. Neoplastic progression and prognosis in melanoma // Semin. Cutan. Med. Surg. - 1996. - № 15. - Р. 336-348.</mixed-citation><mixed-citation xml:lang="en">Elder D.E., Van Belle P., Elenitsas R. et al. Neoplastic progression and prognosis in melanoma // Semin. Cutan. Med. Surg. - 1996. - № 15. - Р. 336-348.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jung J.E., Falk T.M., Bresch М. et al. BRAF mutations in cutaneous melanoma: no correlation with histological prognostic factors or overall survival // Brazilian Journal of Pathology and Laboratory Medicine. - 2010. - Vol. 46, № 6. - Р. 487-493.</mixed-citation><mixed-citation xml:lang="en">Jung J.E., Falk T.M., Bresch М. et al. BRAF mutations in cutaneous melanoma: no correlation with histological prognostic factors or overall survival // Brazilian Journal of Pathology and Laboratory Medicine. - 2010. - Vol. 46, № 6. - Р. 487-493.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Любченко Л.Н., Черненко П.А., Хатырев С.А. и др. Клинико-генетическая гетерогенность меланомы кожи // Злокачественные опухоли. - 2012. - Т. 2, № 2. - C. 81-90.</mixed-citation><mixed-citation xml:lang="en">Любченко Л.Н., Черненко П.А., Хатырев С.А. и др. Клинико-генетическая гетерогенность меланомы кожи // Злокачественные опухоли. - 2012. - Т. 2, № 2. - C. 81-90.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W., Kelly J.W., Trivett M. et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma // J. Invest. Dermatol. - 2007. - Apr. - 127(4). - Р. 900-905.</mixed-citation><mixed-citation xml:lang="en">Liu W., Kelly J.W., Trivett M. et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma // J. Invest. Dermatol. - 2007. - Apr. - 127(4). - Р. 900-905.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shinozaki M., Fujimoto A., Morton D.L. et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas // Clin. Cancer Res. - 2004. - Mar 1. - 10(5). - Р. 1753-1757.</mixed-citation><mixed-citation xml:lang="en">Shinozaki M., Fujimoto A., Morton D.L. et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas // Clin. Cancer Res. - 2004. - Mar 1. - 10(5). - Р. 1753-1757.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Menzies A., Haydu E., Visintin L. et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma // J. Clin. Cancer Res. - June 2012. - № 18. - Р. 3242-3249.</mixed-citation><mixed-citation xml:lang="en">Menzies A., Haydu E., Visintin L. et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma // J. Clin. Cancer Res. - June 2012. - № 18. - Р. 3242-3249.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
